Polyclonal Antibody to Microtubule Associated Protein 1 Light Chain 3 Alpha (MAP1LC3a)
| Code | Size | Price |
|---|
| PAL701Hu01-20ul | 20ul | £93.00 |
Quantity:
| PAL701Hu01-100ul | 100ul | £175.00 |
Quantity:
| PAL701Hu01-200ul | 200ul | £237.00 |
Quantity:
| PAL701Hu01-1ml | 1ml | £547.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
MAP1ALC3; MAP1BLC3; LC3; LC3A; ATG8E; Autophagy-related ubiquitin-like modifier LC3 A; MAP1 light chain 3-like protein 1
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
Microtubule Associated Protein 1 Light Chain 3 Alpha
Reactivity:
Mu;Ra;Po;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;<br/>Immunohistochemistry: 5-20ug/mL;<br/>Immunocytochemistry: 5-20ug/mL;<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Microtubule Associated Protein 1 Light Chain 3 Alpha (MAP1LC3a) | RPL701Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||